Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 222Carcinoma, Renal Cell 84Liver Neoplasms 68Neoplasms 53Leukemia, Myeloid, Acute 37Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 29Melanoma 24Kidney Neoplasms 22Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Thyroid Neoplasms 13Recurrence 13Glioblastoma 13Colorectal Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

ganitumab 3Paclitaxel 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2tislelizumab 1teprotumumab 1dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Lapatinib 1Istiratumab 1Cisplatin 1Carboplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulin-Like Growth Factor I, Resistance To × Sorafenib × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡